Adherence with therapy among patients with multiple sclerosis Original article
Article Sidebar
Main Article Content
Abstract
Background: The medications compliance and adherence are the basis of efficacy and safety of treatment.
Aim: The aim of this study was to assess adherence among patients with multiple sclerosis.
Material and method: Study was conducted among 24 patients with multiple sclerosis, in period from March 2017 to April 2017 in neurological clinic in the Institute of Psychiatry and Neurology in Warsaw. This survey-based study was performed using the author’s questionnaire and the 4-item Morisky-Green test appraising the medication non-adherence.
Results: In total, 13 of study participants have forgotten to take their drugs on some occasion, and 9 of patients neglected their medications hours. However, 4 of participants skip the drugs when they are feeling well, and 7 of participants skip the drugs when they have an adverse reaction to their medications.
Conclusions: Patients with MS should be informed about the benefits of respecting therapeutic recommendations.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kardas P.: Jak poprawić przestrzeganie zaleceń terapeutycznych w Europie: Projekt ABC. Fam. Med. Prim. Rev. 2009; 11(3): 659-661.
3. Morisky D.E., Green L.W., Levine D.M.: Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care 1986; 24(1): 67-74.
4. [online: www.stwardnienierozsiane.com] (dostęp: styczeń 2018).
5. Haase R., Kullmann J.S., Ziemssen T.: Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Ther. Adv. Neurol. Disord. 2016; 9(4): 250-263.
6. Menzin J., Caon C., Nichols C. et al.: Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J. Manag. Care Pharm. 2013; 19(1 Suppl. A): S24-S40.
7. Decoo D., Vokaer M.: Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. Patient Prefer. Adherence 2015; 9: 1669-1676.
8. Devonshire V., Lapierre Y., Macdonell R. et al.: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur. J. Neurol. 2011; 18(1): 69-77.
9. Devonshire V., Lapierre Y., Macdonell R.; the GAP Study Group: The Global Adherence Project (GAP) – a multicentre observational study on adherence to disease- modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Poster presented at: 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 27–30, 2006.
10. Arroyo E., Grau C., Ramo-Tello C. et al.: Adherence to disease-modifying therapies in patients with relapsing multiple sclerosis: two-year interim results of the Global Adherence Project. Eur. Neurol. 2011; 65(2): 59-67.